[1]刘安利,薛茜,苗瑞瑞.2019冠状病毒疾病大流行背景下可逆性后部脑病综合征的特点分析[J].中国临床神经外科杂志,2024,29(04):243-247.[doi:10.13798/j.issn.1009-153X.2024.04.012]
 LIU An-li,XUE Qian,MIAO Rui-rui.Characteristics of posterior reversible encephalopathy syndrome amid the coronavirus disease 2019 pandemic[J].,2024,29(04):243-247.[doi:10.13798/j.issn.1009-153X.2024.04.012]
点击复制

2019冠状病毒疾病大流行背景下可逆性后部脑病综合征的特点分析()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年04期
页码:
243-247
栏目:
综述
出版日期:
2024-04-30

文章信息/Info

Title:
Characteristics of posterior reversible encephalopathy syndrome amid the coronavirus disease 2019 pandemic
文章编号:
1009-153X(2024)04-0243-05
作者:
刘安利薛茜苗瑞瑞
075000河北张家口,河北北方学院研究生院(刘安利);075000河北张家口,河北北方学院附属第一医院神经内一科(薛茜、苗瑞瑞)
Author(s):
LIU An-li1 XUE Qian2 MIAO Rui-rui2
1. Graduate School of North China University of Science and Technology, Zhangjiakou 075000, China; 2. Department of Neurology, Affiliated Hospital of North China University of Science and Technology, Zhangjiakou 075000, China
关键词:
可逆性后部脑病综合征2019冠状病毒疾病COVID-19临床特征
Keywords:
Posterior reversible encephalopathy syndrome Coronavirus disease 2019 COVID-19 Clinical characteristics
分类号:
R 742
DOI:
10.13798/j.issn.1009-153X.2024.04.012
文献标志码:
A
摘要:
在2019冠状病毒疾病(COVID-19)大流行背景下,可逆性后部脑病综合征(PRES)的发病率有所增加。我们通过计算机检索Pubmed、中国知网、万方据库,检索时间为建库到2022年6月;检索到COVID-19合并PRES共45例,均排除了PRES的其他危险因素。综合分析显示,COVID-19合并PRES比单纯PRES可能更容易出现脑出血并发症,COVID-19合并PRES病人的脑出血风险与COVID-19病情严重程度有关;低氧可能是PRES的诱因。
Abstract:
Amid the coronavirus disease 2019 (COVID-19) pandemic, there has been an observed escalation in the incidence of posterior reversible encephalopathy syndrome (PRES). A systematic search was conducted using computerized databases including Pubmed, CNKI, and Wanfang Database from their inception to June 2022. A total of 45 cases of COVID-19 with PRES were identified, all excluding other risk factors for PRES. Our comprehensive analysis revealed that individuals with COVID-19 and PRES may be more susceptible to cerebral hemorrhage complications compared to those with pure PRES. Furthermore, the risk of cerebral hemorrhage in patients with COVID-19 and PRES appears to be associated with the severity of their COVID-19 condition. Additionally, hypoxia may serve as a precipitating factor for PRES.

参考文献/References:

[1]HINCHEY J, CHAVES C, APPIGNANI B, et al. A reversible posterior leukoencephalopathy syndrome [J]. N Engl J Med, 1996, 334(8): 494-500.
[2]ANAND P, LAU KHV, CHUNG DY, et al. Posterior reversible encephalopathy syndrome in patients with coronavirus disease 2019: two cases and a review of the literature [R]. J Stroke Cerebrovasc Dis, 2020, 29(11): 105212.
[3]PARAUDA SC, GAO V, GEWIRTZ AN, et al. Posterior reversible encephalopathy syndrome in patients with COVID-19 [J]. J Neurol Sci, 2020, 416: 117019.
[4]LLANSO L, URRA X. Posterior. reversible encephalopathy syndrome in covid-19 disease: a case-report [J]. SN Compr Clin Med, 2020, 2(10): 1900-1902.
[5]HIXON AM, THAKER AA, PELAK VS. Persistent visual dysfunction following posterior reversible encephalopathy syndrome due to COVID-19: case series and literature review [J]. Eur J Neurol, 2021, 28(10): 3289-3302.
[6]CONTE G, AVIGNONE S, CARBONARA M, et al. COVID-19associated PRES-like encephalopathy with perivascular gadolinium enhancement [J]. AJNR Am J Neuroradiol, 2020, 41(12): 2206-2208.
[7]SHARMA D, TOMAR DS, GUPTA S. Non-hypertension-associated posterior reversible encephalopathy syndrome in COVID-19 [J]. Indian J Crit Care Med, 2022, 26(5): 641-642.
[8]GHOSH R, LAHIRI D, DUBEY S, et al. Hallucinatory palinopsia in COVID-19-induced posterior reversible encephalopathy syndrome [J]. J Neuroophthalmol, 2020, 40(4): 523-526.
[9]COLOMBO A, MARTINELLI BONESCHI F, BERETTA S, et al. Posterior reversible encephalopathy syndrome and COVID-19: a series of 6 cases from Lombardy, Italy [J]. eNeurologicalSci, 2020, 22: 100306.
[10]YAGUCHI H, MITO Y, KODAMA F, et al. Posterior reversible encephalopathy syndrome associated with covid-19 in a Japanese patient [J]. Intern Med, 2021, 60(18): 3055-3056.
[11]MOTOLESE F, FERRANTE M, ROSSI M, et al. Posterior reversible encephalopathy syndrome and brain haemorrhage as COVID-19 complication: a review of the available literature [J]. J Neurol, 2021, 268(12): 4407-4414.
[12]PRINCIOTTA CARIDDI L, TABAEE DAMAVANDI P, CARIMATI F, et al. Reversible encephalopathy syndrome (PRES) in a COVID19 patient[J]. J Neurol, 2020, 267(11): 3157-3160.
[13]KISHFY L, CASASOLA M, BANANKHAH P, et al. Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19 [J]. J Neurol Sci, 2020, 414: 116943.
[14]GOMEZ -ENJUTO S, HERNANDO-REQUEJO V, LAPENAMOTILVA J, et al. Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient [J]. Seizure, 2020, 80: 157-158.
[15]DJELLAOUI A, SEDDIK L, CLERET DE LANGAVANT L, et al. Posterior reversible encephalopathy syndrome associated with SARS-CoV-2 infection [J]. JNNP, 2020, 92: 113-114.
[16]FRANCESCHI AM, AHMED O, GILIBERTO L, et al. Hemorrhagic posterior reversible encephalopathy syndrome as a manifestation of COVID-19 infection [J]. AJNR Am J Neuroradiol, 2020, 41(7): 1173-1176.
[17]IOAN P, RIBIGAN AC, RUSU O, et al. Posterior reversible encephalopathy syndrome--a pathology that should not be overlooked in the era of COVID-19 [J]. Am J Emerg Med, 2022, 56: 393.e5-393.e8.
[18]KOBAIDZE K, SHIN YM, JAPARIDZE M, et al. Posterior reversible leukoencephalopathy syndrome in a patient after acute COVID-19 infection [J]. Case Rep Neurol Med, 2021, 2021: 5564802.
[19]MARTINS JF, CRUZ LR, PEREIRA DJ, et al. Posterior reversible encephalopathy syndrome in a patient submitted to extracorporeal membrane oxygenation for COVID-19 [J]. Rev Bras Ter Intensiva, 2021, 33(3): 457-460.
[20]TALLURI K, LALL N, MORENO MA, et al. Posterior reversible encephalopathy syndrome in a patient with SARS-CoV-2 infection treated with tocilizumab [J]. Cureus, 2021, 13(2): e13475.
[21]LALLANA S, CHEN A, REQUENA M, et al. Posterior reversible encephalopathy syndrome (PRES) associated with COVID-19 [J]. J Clin Neurosci, 2021, 88: 108-112.
[22]ORDONEZ-BOSCHETTI L, TORRES-ROMERO CM, ORTIZDE LEO MJ. Associated posterior reversible encephalopathy syndrome (PRES) to SARS-CoV-2 [J]. Neurologia (Engl Ed), 2020, 35(9): 696-698.
[23]ELHASSAN M, SAIDAHMED O, ADEBAYO A, et al. Persistent cortical blindness following posterior reversible encephalopathy syndrome (PRES) as a complication of COVID-19 pneumonia [J]. Cureus, 2021, 13(1): e12794.
[24]FISCHER M, SCHMUTZHARD E. Posterior reversible encephalopathy syndrome [J]. J Neurol, 2017, 264(8): 1608-1616.
[25]KASTRUP O, GERWIG M, FRINGS M, et al. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns [J]. J Neurol, 2012, 259(7): 1383-1389.
[26]GEWIRTZ AN, GAO V, PARAUDA SC, et al. Posterior reversible encephalopathy syndrome [J]. Curr Pain Headache Rep, 2021, 25 (3): 19.
[27]LIMAN TG, SIEBERT E, ENDRES M. Posterior reversible encephalopathy syndrome [J]. Curr Opin Neurol, 2019, 32(1): 25-35.
[28]GOEL K, KUMAR A, DIWAN S, et al. Neurological manifestations of COVID-19: a series of seven cases [J]. Indian J Crit Care Med, 2021, 25(2): 219-223.
[29]ZIRPE KG, DIXIT S, KULKARNI AP, et al. Pathophysiological mechanisms and neurological manifestations in COVID-19 [J]. Indian J Crit Care Med, 2020, 24(10): 975-980.
[30]BARTYNSKI WS, BOARDMAN JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome [J]. AJNR Am J Neuroradiol, 2007, 28(7): 1320-1327.
[31]LAMY C, OPPENHEIM C, MEDER JF, et al. Neuroimaging in posterior reversible encephalopathy syndrome [J]. J Neuroimaging, 2004, 14: 89-96.
[32]PARASHER A, JHAMB R. Posterior reversible encephalopathy syndrome (PRES): presentation, diagnosis and treatment [J]. Postgrad Med J, 2020, 96(1140): 623-628.
[33]DANDOY CE, LINSCOTT LL, DAVIES SM, et al. Clinical utility of computed tomography and magnetic resonance imaging for diagnosis of posterior reversible encephalopathy syndrome after stem cell transplantation in children and adolescents [J]. Biol Blood Marrow Transplant, 2015, 21(11): 2028-2032.
[34]FUGATE JE, RABINSTEIN AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions [J]. Lancet Neurol, 2015, 14(9): 914-925.
[35]PAULSON OB, WALDEMAR G, SCHMIDT JF, et al. Cerebral circulation under normal and pathologic conditions [J]. Am J Cardiol, 1989, 63: 2C-5C.
[36]LI Y, GOR D, WALICKI D, et al. Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome [J]. J Stroke Cerebrovasc Dis, 2012, 21(8): 873-882.
[37]FESKE SK. Posterior reversible encephalopathy syndrome: a review [J]. Semin Neurol, 2011, 31(2): 202-215.
[38]MARRA A, VARGAS M, STRIANO P, et al. Posterior reversible encephalopathy syndrome: the endothelial hypotheses [J]. Med Hypotheses, 2014, 82(5): 619-622.
[39]WRAPP D, WANG N, CORBETT KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation [J]. Science, 2020, 367(6483): 1260-1263.
[40]HU B, HUANG S, YIN L. The cytokine storm and COVID-19 [J]. J Med Virol, 2021, 93(1): 250-256.
[41]POLLARD CA, MORRAN MP, NESTOR-KALINOSKI AL. The COVID-19 pandemic: a global health crisis [J]. Physiol Genomics, 2020, 52(11): 549-557.
[42]ZHANG H, PENNINGER JM, LI Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target [J]. Intensive Care Med, 2020, 46(4): 586-590.
[43]ALLEN JA, ADLAKHA A, BERGETHON PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer [J]. Arch Neurol, 2006, 63(10): 1475-1478.
[44]CHARDAIN A, MESNAGE V, ALAMOWITCH S, et al. Posterior reversible encephalopathy syndrome (PRES) and hypomagnesemia: a frequent association [J]. Rev Neurol (Paris), 2016, 172(6-7): 384-388.
[45]YAMAGAMI K, MAEDA Y, IIHARA K. Variant type of posterior reversible encephalopathy syndrome associated with deep brain hemorrhage: case report and review of the literature [J]. World Neurosurg, 2020, 134: 176-181.
[46]GRANATA G, GRECO A, IANNELLA G, et al. Posterior reversible encephalopathy syndrome--Insight into pathogenesis, clinical variants and treatment approaches [J]. Autoimmun Rev, 2015, 14(9): 830-836.
[47]MANCIA G, FAGARD R, NARKIEWICZ K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. Eur Heart J, 2013, 31(7): 1281-1357.
[48]COZZOLINO M, BIANCHI C, MARIANI G, et al.Therapy and differential diagnosis of posterior reversible encephalopathy syndrome (PRES) during pregnancy and postpartum [J]. Arch Gynecol Obstet, 2015, 292(6): 1217-1223.
[49]MASETTI R, CORDELLI DM, ZAMA D, et al. PRES in children undergoing hematopoietic stem cell or solid organ transplantation [J]. Pediatrics, 2015, 135(5): 890-901.
[50]MORIGUCHI T, HARII N, GOTO J, et al. A first case of meningitis/ encephalitis associated with SARS-Coronavirus-2 [J]. Int J Infect Dis, 2020, 94: 55-58.

备注/Memo

备注/Memo:
(2023-01-06收稿,2024-01-12修回)
更新日期/Last Update: 2024-04-30